Search

Elaine M Liversidge

from Charlestown, MA
Age ~75
Get Report
Also known as:
Elaine M Merisko
Phone and address:
250 1St Ave UNIT 526, Boston, MA 02129
Related to:
Gary George Liversidge, 69Roy G Liversidge, 50
Connected to:
Alexander H Liversidge, 70Joshua W Lives, 51Allen W Livesay, 75Barbara J Livesay, 76Devon T Livesay, 33Evan Livesay, 44Laurie N Livesay, 35Mark F Livesay, 65Patricia A Livesay, 71Shalu L Livesay, 49

Elaine Liversidge Phones & Addresses

  • 250 1St Ave UNIT 526, Charlestown, MA 02129
  • 258 Colwyn Ter, West Chester, PA 19380 (610) 696-7774
  • New Haven, CT
  • Kansas City, MO
  • 250 1St Ave UNIT 526, Charlestown, MA 02129 (610) 696-7774

Resumes

Resumes

Elaine Liversidge Photo 1

Elaine Liversidge

View page
Location:
Charlestown, MA
Industry:
Pharmaceuticals
Work:
Alkermes
Retired, R and D Senior Director
Elaine Liversidge Photo 2

Senior Director

View page
Location:
265 Olinger Cir, Wilmington, OH 45177
Industry:
Biotechnology
Work:
Alkermes
Senior Director

Publications

Us Patents

Reduction Of Intravenously Administered Nanoparticulate-Formulation-Induced Adverse Physiological Reactions

View page
US Patent:
RE41884, Oct 26, 2010
Filed:
Feb 6, 2008
Appl. No.:
12/027100
Inventors:
Lawrence de Garavilla - Downington PA, US
Elaine Liversidge - West Chester PA, US
Gary G. Liversidge - West Chester PA, US
Assignee:
Elan Pharma International Limited - Co. Clare
International Classification:
A61K 9/50
B32B 5/16
B01J 13/02
US Classification:
424501, 424502, 42840221, 264 43, 977700, 977904
Abstract:
Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations.

Nanoparticulate Compositions Having A Peptide As A Surface Stabilizer

View page
US Patent:
7879360, Feb 1, 2011
Filed:
Nov 2, 2004
Appl. No.:
10/978695
Inventors:
James Cunningham - Malvern PA, US
Elaine Merisko Liversidge - West Chester PA, US
Assignee:
Elan Pharma International, Ltd. - Athlone, County Westmeath
International Classification:
A61K 9/14
A61K 9/16
A61K 9/20
A61K 9/48
US Classification:
424489, 424451, 424464, 424490
Abstract:
The present invention is directed to nanoparticulate active agent compositions comprising at least one peptide as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Injectable Nanoparticulate Olanzapine Formulations

View page
US Patent:
7910577, Mar 22, 2011
Filed:
Nov 16, 2005
Appl. No.:
11/274887
Inventors:
Gary Liversidge - West Chester PA, US
Scott Jenkins - Downingtown PA, US
Elaine Merisko Liversidge - West Chester PA, US
Assignee:
Elan Pharma International Limited - Athlone, County Westmeath
International Classification:
A61K 31/55
A01N 43/00
A01N 43/46
C07D 243/10
US Classification:
514220, 977902, 977904, 977905, 977906, 977915, 540557
Abstract:
Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.

Pharmaceutical Composition Of A Tachykinin Receptor Antagonist

View page
US Patent:
8258132, Sep 4, 2012
Filed:
Dec 9, 2002
Appl. No.:
10/317948
Inventors:
H. William Bosch - Bryn Mawr PA, US
Elaine Liversidge - West Chester PA, US
Suhas D. Shelukar - Lansdale PA, US
Karen C. Thompson - Lansdale PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 9/14
A61K 9/00
A61K 31/41
A61K 31/535
US Classification:
5142315, 424 46, 424489, 514383, 514384
Abstract:
The present invention is directed to novel pharmaceutical compositions of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine. The pharmaceutical compositions of this invention useful in the treatment or prevention of disorders such as psychiatric disorders including depression and anxiety, inflammatory diseases and emesis.

Stabilization Of Chemical Compounds Using Nanoparticulate Formulations

View page
US Patent:
20030054042, Mar 20, 2003
Filed:
Sep 14, 2001
Appl. No.:
09/952032
Inventors:
Elaine Liversidge - West Chester PA, US
Linden Wei - Exton PA, US
International Classification:
A61K009/14
US Classification:
424/489000
Abstract:
Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or exposure to non-physiological pH conditions.

Nanoparticulate Insulin

View page
US Patent:
20030095928, May 22, 2003
Filed:
Sep 19, 2002
Appl. No.:
10/246751
Inventors:
Simon McGurk - King of Prussia PA, US
Elaine Liversidge - West Chester PA, US
Daniel O'Mahoney - Dublin, IE
Amy Weiderhold - North Wales PA, US
Araz Raoof - Dublin, IE
Assignee:
Elan Pharma International Limited
International Classification:
A61K038/28
A61L009/04
A61K009/14
US Classification:
424/046000, 514/003000
Abstract:
Nanoparticulate insulin compositions having effective an average particle size of less than about 5 microns are described. The compositions exhibit retention of insulin bioactivity, increased bioavailability, and increased consistency of bioavailability as compared to prior macro-sized insulin compositions. Methods of making nanoparticulate insulin compositions, dosage forms containing them, and the use of such formulations in insulin therapy are also described.

Nanoparticulate Nystatin Formulations

View page
US Patent:
20040018242, Jan 29, 2004
Filed:
May 5, 2003
Appl. No.:
10/429245
Inventors:
James Cunningham - Malvern PA, US
Elaine Liversidge - West Chester PA, US
Assignee:
Elan Pharma International Ltd.
International Classification:
A61K031/7048
A61K009/14
US Classification:
424/489000, 514/027000
Abstract:
The present invention is directed to nanoparticulate compositions comprising nystatin. The nystatin particles of the composition have an effective average particle size of less than about 2000 nm.

Milling Microgram Quantities Of Nanoparticulate Candidate Compounds

View page
US Patent:
20040173696, Sep 9, 2004
Filed:
Dec 17, 2003
Appl. No.:
10/736989
Inventors:
James Cunningham - Paoli PA, US
Elaine Liversidge - West Chester PA, US
Eugene Cooper - Berwyn PA, US
Gary Liversidge - West Chester PA, US
Assignee:
Elan Pharma International Ltd.
International Classification:
B02C019/12
US Classification:
241/021000
Abstract:
The present invention is directed to a method of milling small quantities of one or more candidate compounds to reduce the particle size of at least one candidate compound to about 2 microns or less. The apparatus used for the milling process can be one or more multi-well plates, or any other suitable apparatus. The resultant products are dispersions of nanoparticulate candidate compounds. The method is particularly suited for increasing the effectiveness of high throughput screening (“HTS”).
Control profile
Elaine M Liversidge from Charlestown, MA, age ~75 Get Report